Initial experience with CytoSorb therapy in patients receiving left ventricular assist devices

Initial experience with CytoSorb therapy in patients receiving left ventricular assist devices

Background The use of left ventricular assist devices (LVAD) in patients with advance heart failure is still associated with an important risk of immune dysregulation and infections. The aim of this study was to determine whether extracorporeal blood purification using the CytoSorb device benefits p...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Artificial organs 2022-01, Vol.46 (1), p.95-105
Hauptverfasser: Zhigalov, Konstantin, Van den Eynde, Jef, Zubarevich, Alina, Chrosch, Thomas, Goerdt, Lukas, Arjomandi Rad, Arian, Vardanyan, Robert, Sá, Michel Pompeu Barros Oliveira, Luedike, Peter, Pizanis, Nikolaus, Koch, Achim, Schmack, Bastian, Kamler, Markus, Ruhparwar, Arjang, Weymann, Alexander
Format: Artikel
Sprache:eng
Schlagworte:
C-Reactive Protein - analysis
Complications
Congestive heart failure
cytosorb
Female
Heart Failure - therapy
Heart-Assist Devices - adverse effects
hemadsorption
Hemofiltration - instrumentation
Hemofiltration - methods
Hospital Mortality
Humans
Implantation
Interleukin-6 - blood
left ventricular assist device
Leukocyte Count
Male
Mechanical ventilation
Middle Aged
Morbidity
Mortality
Ostomy
Patients
Respiration, Artificial - statistics & numerical data
Respiratory failure
Respiratory Insufficiency
Retrospective Studies
Survival
Tracheostomy
Tracheotomy - statistics & numerical data
Treatment Outcome
Ventricle
Ventricular assist devices
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background The use of left ventricular assist devices (LVAD) in patients with advance heart failure is still associated with an important risk of immune dysregulation and infections. The aim of this study was to determine whether extracorporeal blood purification using the CytoSorb device benefits patients after LVAD implantation in terms of complications and overall survival. Materials and Methods Between August 2010 and January 2020, 207 consecutive patients underwent LVAD implantation, of whom 72 underwent CytoSorb therapy and 135 did not. Overall survival, major adverse events, and laboratory parameters were compared between 112 propensity score‐matched patients (CytoSorb: 72 patients; non‐CytoSorb: 40 patients). Results WBC (p = .033), CRP (p = .001), and IL‐6 (p 
ISSN:0160-564X
1525-1594
DOI:10.1111/aor.14099